Physiological Effects of Altering Cancer-related Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective pilot study will examine whether the previously reported effects of NSAIDs on colorectal cancer may be modulated through alterations in tissue gene expression, up regulation of local immune cell infiltrates or down-regulation of the systemic inflammatory response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk

NCT02945033

Colorectal Cancer

UNKNOWN PHASE3

Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

NCT00002527

Colorectal Cancer

COMPLETED PHASE3

Molecular Effects of Aspirin & Metformin on Colonic Epithelium

NCT05158374

Colorectal Cancer Colorectal Neoplasms Colorectal Adenoma

WITHDRAWN NA

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

NCT02965703

Colorectal Adenoma Colorectal Carcinoma

ACTIVE_NOT_RECRUITING PHASE2

Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

NCT03170115

Rectal Cancer, Adenocarcinoma Locally Advanced Malignant Neoplasm Chemoradiation

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bowel cancer is the second commonest cause of death from cancer in the UK. Of patients who have an apparently curative operation, half unfortunately suffer disease recurrence and die before 5 years. Clearly more research is required to improve outcomes in this condition. Most current research focuses on antitumour strategies, however the reaction of the patient (host) to the tumour is also important. The host inflammatory responses to the cancer are likely to represent part of this host-tumour relationship. Inflammation plays an important role in predicting patients who will die. Currently it is not known whether antiinflammatory drugs have any effect on cancer related inflammation detected in the blood or in/around the tumour.

Aims: We hope to demonstrate that tumour related inflammation in bowel cancer can be altered using anti- inflammatory drugs. This may form the rationale for the use of antiinflammatory drugs to improve prognosis in colorectal cancer patients undergoing surgery.

Methods: This pilot study will investigate whether simple antiinflammatory drugs can alter markers of inflammation both in the blood and in/around the tumour. Patients having bowel cancer surgery will be prescribed one of two anti-inflammatory drugs (aspirin 75mg once daily or ibuprofen 400mg three times daily) for 2 to 3 weeks prior to their operation. Blood and tumour samples before and after the treatment will be analysed.

If the study's aims are met and cancer-related inflammation can be altered prior to surgery, then a larger scale drug trial will be proposed to demonstrate reduced cancer recurrence and improved survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin

20 patients randomised to aspirin 75mg PO once daily

Group Type ACTIVE_COMPARATOR

Aspirin

Intervention Type DRUG

Ibuprofen

20 patients randomised to ibuprofen 400mg PO three times daily

Group Type ACTIVE_COMPARATOR

Ibuprofen

Intervention Type DRUG

Control

20 patients randomised to receive no treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspirin

Intervention Type DRUG

Ibuprofen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged 18 to 75 years old
* histologically confirmed colon cancer
* evidence of systemic inflammation (C-reactive protein \>10mg/l)
* candidate for elective primary curative resection

Exclusion Criteria

* Age \<18yrs or \>75yrs
* emergency presentation
* rectal cancer
* distal metastatic disease at presentation
* provision of neo-adjuvant chemo-radiotherapy
* long-term use of aspirin or anti-inflammatory medications (NSAIDS, or steroids
* hypersensitivity to product or excipients or evidence of previous hypersensitivity reactions such as asthma, rhinitis, angioedema or urticaria in response to aspirin, ibuprofen or other NSAID
* intolerance of NSAIDs/ aspirin due to allergy or side effects
* active peptic ulcer disease
* previous history of recurrent gastrointestinal bleeding or bleeding/perforation secondary to previous NSAID use
* previous treatment for gastrointestinal cancer
* alcohol excess (above recommended guidelines)
* chronic renal impairment
* moderate to severe heart failure
* hepatic impairment

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No